Written question asked by Kerry McCarthy (Labour) on Wednesday, 15 April 2026, in the House of Commons. It was due for an answer on Wednesday, 22 April 2026 (named day). A holding answer was provided on Thursday, 23 April 2026. A substantive answer was provided by Zubir Ahmed (Labour) on Tuesday, 28 April 2026 on behalf of the Department of Health and Social Care.
Advanced Therapy Medicinal Products
- Question
-
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of regenerative medicine techniques on surgical recovery.
- Answer
-
Regenerative techniques, such as cell therapies, growth factors, and bioengineered scaffolds, can accelerate wound healing, which is particularly valuable in complex or high‑risk surgeries. NHS England maintains an overview of the advanced therapy medicinal products in development and assesses the potential National Health Service impact and the requirements for individual treatments as part of its due diligence, ensuring the NHS is ready to deliver innovative new treatments that secure a positive Medicines and Healthcare products Regulatory Agency licensing decision and National Institute for Health and Care Excellence recommendation.
Secondary information
- Type
- Written question
- Reference
- 127427
- Session
- 2024-26
- Subjects
- Advanced therapy medicinal products
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-04-28 23:41:36 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/127427
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/127427
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/127427